Issues
-
Cover Image
Cover Image
Angiogenesis is critical for tumor nutrient access and progression, rendering it an attractive therapeutic target. To date, antiangiogenic therapies have lacked success due to side effects and therapeutic resistance. Therefore, antiangiogenic therapy may be enhanced using novel molecular targets that regulate angiogenesis and other oncogenic processes. In their study on page 77, Kumar and colleagues demonstrate that in addition to previously established roles in epithelial–mesenchymal transition and poor patient outcomes, IQGAP2 suppression induces breast tumor angiogenesis. The cover depicts an ImageJ Angiogenesis Analyzer image of human umbilical vein endothelial cell tubules in culture with conditioned medium from breast cancer cells in which IQGAP2 expression has been reduced using shRNA. This article is also Highlighted on page 1. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Minireview
Reviews
Rapid Impact
Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Cancer Genes and Networks
GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer
Cancer “-omics”
Mutations in Noncoding Cis-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer
Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway
New Horizons in Cancer Biology
A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
Heme Sequestration Effectively Suppresses the Development and Progression of Both Lung Adenocarcinoma and Squamous Cell Carcinoma
Signal Transduction and Functional Imaging
Tumor Microenvironment and Immunobiology
Epstein-Barr Virus Induces Lymphangiogenesis and Lympth Node Metastasis via Upregulation of VEGF-C in Nasopharyngeal Carcinoma
Correction
Acknowledgment to Reviewers
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.